Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074 Aachen, Germany; Institute for Molecular Biotechnology, Worringerweg 1, RWTH Aachen University, 52074 Aachen, Germany.
Biotechnol Adv. 2018 Mar-Apr;36(2):506-520. doi: 10.1016/j.biotechadv.2018.02.002. Epub 2018 Feb 3.
Herbal remedies were the first medicines used by humans due to the many pharmacologically active secondary metabolites produced by plants. Some of these metabolites inhibit cell division and can therefore be used for the treatment of cancer, e.g. the mitostatic drug paclitaxel (Taxol). The ability of plants to produce medicines targeting cancer has expanded due to the advent of genetic engineering, particularly in recent years because of the development of gene editing systems such as the CRISPR/Cas9 platform. These technologies allow the introduction of genetic modifications that facilitate the accumulation of native pharmaceutically-active substances, and even the production heterologous recombinant proteins, including human antibodies, lectins and vaccine candidates. Here we discuss the anti-cancer agents that are produced by plants naturally or following genetic modification, and the potential of these products to supply modern healthcare systems. Special emphasis will be put on proteinaceous anti-cancer agents, which can exhibit an improved selectivity and reduced side effects compared to small molecule-based drugs.
由于植物产生的许多具有药理活性的次生代谢物,草药是人类最早使用的药物。其中一些代谢物抑制细胞分裂,因此可用于治疗癌症,例如有丝分裂抑制剂紫杉醇(Taxol)。由于基因工程的出现,植物产生针对癌症的药物的能力得到了扩展,特别是近年来,由于基因编辑系统(如 CRISPR/Cas9 平台)的发展更是如此。这些技术允许引入有助于积累天然药物活性物质的遗传修饰,甚至可以生产异源重组蛋白,包括人抗体、凝集素和疫苗候选物。在这里,我们讨论了天然或经过遗传修饰的植物产生的抗癌剂,以及这些产品为现代医疗保健系统提供的潜力。特别强调的是蛋白质类抗癌剂,与基于小分子的药物相比,它们具有更高的选择性和更低的副作用。